Copy to clipboard 
Enovis reported 2Q25 orthopedic sales of $284.1 million, up 8.5% compared to the second quarter of 2024. For the first half of 2025, the company generated $584.7 million in orthopedic sales, up 9.6% compared to the prior period.
New Enovis CEO Damien McDonald identified enabling technology as a particular focus for the company’s innovation pipeline efforts going forward, as it has the highest differentiation and market potential.
“With respect to enabling tech and robotics, look, we’ve clearly heard the message that enabling tech is a key part of having a complete global portfolio,” said Mr. McDonald. “Our first solution is focusing on the steps of planning and navigation. We’re still continuing to examine whether large-format robots are cost-effective solutions and improve patient outcomes, and whether entry into the market at this point is really valid.”
Enovis’ augmented reality platform, Arvis, has shown significant promise for multiple anatomies but the company is about six months behind in launching the next-generation version of the platform.
The upcoming version will feature a lighter headset, improved visualization, faster registration, enhanced tracking and future expandability for soft tissue balancing.
The company updated its 2025 total sales guidance to the range between $2.245 billion and $2.275 billion.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $232.2 | $214.0 | $18.2 | 8.5% |
| Knees | $56.2 | $52.0 | $4.2 | 8.1% |
| Hips | $76.7 | $71.7 | $5.0 | 6.9% |
| Extremities | $99.3 | $90.3 | $9.0 | 10% |
| Trauma | $27.4 | $26.0 | $1.4 | 5.5% |
| Other | $24.6 | $22.0 | $2.5 | 11.6% |
| Total | $284.1 | $262.0 | $22.2 | 8.5% |
| Segment | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $482.1 | $437.8 | $44.3 | 10.1% |
| Knees | $114.8 | $103.4 | $11.4 | 11.1% |
| Hips | $159.7 | $146.4 | $13.4 | 9.1% |
| Extremities | $207.5 | $188.1 | $19.5 | 10.3% |
| Trauma | $55.2 | $51.7 | $3.5 | 6.7% |
| Other | $47.5 | $44.0 | $3.5 | 7.9% |
| Total | $584.7 | $533.5 | $51.2 | 9.6% |
Orthopedic Sales by Geography
| Region | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $134.3 | $129.3 | $5.0 | 3.9% |
| OUS | $149.8 | $132.7 | $17.1 | 12.9% |
| EMEA | $120.8 | $106.1 | $14.7 | 13.8% |
| APAC | $18.5 | $17.0 | $1.4 | 8.5% |
| ROW | $10.6 | $9.6 | $1.0 | 10.6% |
| Total | $284.1 | $262.0 | $22.2 | 8.5% |
| Region | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $279.1 | $259.8 | $19.2 | 7.4% |
| OUS | $305.6 | $273.6 | $32.0 | 11.7% |
| EMEA | $244.7 | $217.4 | $27.3 | 12.6% |
| APAC | $38.8 | $36.0 | $2.7 | 7.6% |
| ROW | $22.1 | $20.2 | $1.9 | 9.6% |
| Total | $584.7 | $533.5 | $51.2 | 9.6% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $564.5 | |
| Cost of Sales | $229.8 | 40.7% |
| Selling and Admin | $267.1 | 47.3% |
| R&D | $30.7 | 13.4% |
| Other | $104.4 | 18.5% |
| Net Earnings | ($36.7) | (6.5%) |
Enovis reported 2Q25 orthopedic sales of $284.1 million, up 8.5% compared to the second quarter of 2024. For the first half of 2025, the company generated $584.7 million in orthopedic sales, up 9.6% compared to the prior period.
New Enovis CEO Damien McDonald identified enabling technology as a particular focus for the company's innovation...
Enovis reported 2Q25 orthopedic sales of $284.1 million, up 8.5% compared to the second quarter of 2024. For the first half of 2025, the company generated $584.7 million in orthopedic sales, up 9.6% compared to the prior period.
New Enovis CEO Damien McDonald identified enabling technology as a particular focus for the company’s innovation pipeline efforts going forward, as it has the highest differentiation and market potential.
“With respect to enabling tech and robotics, look, we’ve clearly heard the message that enabling tech is a key part of having a complete global portfolio,” said Mr. McDonald. “Our first solution is focusing on the steps of planning and navigation. We’re still continuing to examine whether large-format robots are cost-effective solutions and improve patient outcomes, and whether entry into the market at this point is really valid.”
Enovis’ augmented reality platform, Arvis, has shown significant promise for multiple anatomies but the company is about six months behind in launching the next-generation version of the platform.
The upcoming version will feature a lighter headset, improved visualization, faster registration, enhanced tracking and future expandability for soft tissue balancing.
The company updated its 2025 total sales guidance to the range between $2.245 billion and $2.275 billion.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $232.2 | $214.0 | $18.2 | 8.5% |
| Knees | $56.2 | $52.0 | $4.2 | 8.1% |
| Hips | $76.7 | $71.7 | $5.0 | 6.9% |
| Extremities | $99.3 | $90.3 | $9.0 | 10% |
| Trauma | $27.4 | $26.0 | $1.4 | 5.5% |
| Other | $24.6 | $22.0 | $2.5 | 11.6% |
| Total | $284.1 | $262.0 | $22.2 | 8.5% |
| Segment | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $482.1 | $437.8 | $44.3 | 10.1% |
| Knees | $114.8 | $103.4 | $11.4 | 11.1% |
| Hips | $159.7 | $146.4 | $13.4 | 9.1% |
| Extremities | $207.5 | $188.1 | $19.5 | 10.3% |
| Trauma | $55.2 | $51.7 | $3.5 | 6.7% |
| Other | $47.5 | $44.0 | $3.5 | 7.9% |
| Total | $584.7 | $533.5 | $51.2 | 9.6% |
Orthopedic Sales by Geography
| Region | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $134.3 | $129.3 | $5.0 | 3.9% |
| OUS | $149.8 | $132.7 | $17.1 | 12.9% |
| EMEA | $120.8 | $106.1 | $14.7 | 13.8% |
| APAC | $18.5 | $17.0 | $1.4 | 8.5% |
| ROW | $10.6 | $9.6 | $1.0 | 10.6% |
| Total | $284.1 | $262.0 | $22.2 | 8.5% |
| Region | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $279.1 | $259.8 | $19.2 | 7.4% |
| OUS | $305.6 | $273.6 | $32.0 | 11.7% |
| EMEA | $244.7 | $217.4 | $27.3 | 12.6% |
| APAC | $38.8 | $36.0 | $2.7 | 7.6% |
| ROW | $22.1 | $20.2 | $1.9 | 9.6% |
| Total | $584.7 | $533.5 | $51.2 | 9.6% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $564.5 | |
| Cost of Sales | $229.8 | 40.7% |
| Selling and Admin | $267.1 | 47.3% |
| R&D | $30.7 | 13.4% |
| Other | $104.4 | 18.5% |
| Net Earnings | ($36.7) | (6.5%) |
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
